Hursitoglu, O. Et Al. 2022. Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study. NEUROPSYCHIATRIC DISEASE AND TREATMENT , vol.18 , 2519-2527.

Hursitoglu, O., Kurutas, E. B., Strawbridge, R., Uygur, Ö. F., Yildiz, E., & Reilly, T. J., (2022). Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study. NEUROPSYCHIATRIC DISEASE AND TREATMENT , vol.18, 2519-2527.

Hursitoglu, Onur Et Al. "Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study," NEUROPSYCHIATRIC DISEASE AND TREATMENT , vol.18, 2519-2527, 2022

Hursitoglu, Onur Et Al. "Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study." NEUROPSYCHIATRIC DISEASE AND TREATMENT , vol.18, pp.2519-2527, 2022

Hursitoglu, O. Et Al. (2022) . "Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study." NEUROPSYCHIATRIC DISEASE AND TREATMENT , vol.18, pp.2519-2527.

@article{article, author={Onur Hursitoglu Et Al. }, title={Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study}, journal={NEUROPSYCHIATRIC DISEASE AND TREATMENT}, year=2022, pages={2519-2527} }